Stoky
Back to explore
N
NoahListening
A
AshListening
0:00 / 0:00I. Financial Performance and Segment Results
CRL logo

Charles River Labs Q3 Revenue Dips 0.5% but Operating Income Surges 14%

CRL10-QFiling Date: 11/6/2025
Charles River Laboratories International, Inc.
Description

What this story covers

Charles River Laboratories' Q3 2025 revenue fell 0.5% to $1.005B amid biopharma caution, but operating income rose 14% to $134M on cost cuts. RMS grew 8%, offsetting DSA and Manufacturing declines. Strong cash flow $590M supports restructuring for $225M savings and $1B buybacks. Legal NHP probes ongoing but DOJ cleared.

Story snapshot

CompanyCharles River Laboratories International, Inc.
TickerCRL
VariantStandard detailed
Duration15:27
Filing type10-Q
PeriodQ3 2025
IndustryHealthcare & Pharmaceuticals
Accession0001100682-25-000043

Full Story Script

Content not available for this story.

Ask Noah

Question the story, source filings, and key financial signals.

Sign in to chat with Noah

Ask questions about revenue, margins, risk factors, filings and more. Noah uses retrieval-augmented analysis over raw financial disclosures.

Sign in